TY - JOUR
T1 - New and Emerging Therapies for Pediatric Atopic Dermatitis
AU - Nguyen, Henry L.
AU - Anderson, Katelyn R.
AU - Tollefson, Megha M.
N1 - Publisher Copyright:
© 2019, Springer Nature Switzerland AG.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.
AB - Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.
UR - http://www.scopus.com/inward/record.url?scp=85070342323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070342323&partnerID=8YFLogxK
U2 - 10.1007/s40272-019-00342-w
DO - 10.1007/s40272-019-00342-w
M3 - Review article
C2 - 31364023
AN - SCOPUS:85070342323
SN - 1174-5878
VL - 21
SP - 239
EP - 260
JO - Pediatric Drugs
JF - Pediatric Drugs
IS - 4
ER -